Multiscale Modeling of Hospital Length of Stay for Successive SARS-CoV-2 Variants: A Multi-State Forecasting Framework.

Publication date: Jul 06, 2025

Understanding how hospital length of stay (LoS) evolves with successive SARS-CoV-2 variants is central to the multiscale modeling and forecasting of COVID-19 and other respiratory virus dynamics. Using records from 1249 COVID-19 patients admitted to Chungbuk National University Hospital (2021-2023), we quantified LoS across three distinct variant phases (Pre-Delta, Delta, and Omicron) and three age groups (0-39, 40-64, and 65+ years). A gamma-distributed multi-state model-capturing transitions between semi-critical and critical wards-incorporated variant phase and age as log-linear covariates. Parameters were estimated via maximum likelihood with 95% confidence intervals derived from bootstrap resampling, and Monte Carlo iterations yielded detailed LoS distributions. Omicron-phase stays were 5-8 days, shorter than the 10-14 days observed in earlier phases, reflecting improved treatment protocols and reduced virulence. Younger adults typically stayed 3-5 days, whereas older cohorts required 8-12 days, with prolonged admissions (over 30 days) clustering in the oldest group. These time-dependent transition probabilities can be integrated with real-time bed-availability alert systems, highlighting the need for variant-specific ward/ICU resource planning and underscoring the importance of targeted management for elderly patients during current and future pandemics.

Open Access PDF

Concepts Keywords
Carlo Adolescent
Hospital Adult
Virulence Aged
Viruses Aged, 80 and over
Child
Child, Preschool
COVID-19
COVID-19
Female
Forecasting
Hospitalization
Humans
Infant
Infant, Newborn
Length of Stay
Male
Middle Aged
multi-state model
parameter estimation
SARS-CoV-2
South Korea
Young Adult

Semantics

Type Source Name
disease MESH COVID-19
disease IDO virulence
drug DRUGBANK Etodolac
drug DRUGBANK Coenzyme M
disease MESH immunocompromised patients
disease MESH death
disease MESH Uncertainty
disease MESH infection
disease MESH critically ill
disease IDO process
disease IDO history
disease IDO pathogen
disease MESH influenza
disease MESH comorbidity
drug DRUGBANK Serine
disease MESH emergency
disease MESH cardiac arrest
drug DRUGBANK Troleandomycin
drug DRUGBANK Guanosine
disease MESH clinical significance
drug DRUGBANK Water
disease IDO algorithm
disease IDO intervention
drug DRUGBANK Naproxen
disease MESH pneumonia

Original Article

(Visited 2 times, 1 visits today)